In Vitro Activity of Lascufloxacin against Streptococcus pneumoniae with Mutations in the Quinolone Resistance-Determining Regions | Zendy

Mika Murata | Zendy; Kosuke Kosai | Zendy; Shunsuke Yamauchi | Zendy; Daisuke Sasaki | Zendy; Norihito Kaku | Zendy; Naoki Uno | Zendy; Yoshitomo Morinaga | Zendy; Hiroo Hasegawa | Zendy; Taiga Miyazaki | Zendy; Koichi Izumikawa | Zendy; Hiroshi Mukae | Zendy; Katsunori Yanagihara | Zendy

Open Access

In Vitro Activity of Lascufloxacin against Streptococcus pneumoniae with Mutations in the Quinolone Resistance-Determining Regions

Author(s) -

Mika Murata,

Kosuke Kosai,

Shunsuke Yamauchi,

Daisuke Sasaki,

Norihito Kaku,

Naoki Uno,

Yoshitomo Morinaga,

Hiroo Hasegawa,

Taiga Miyazaki,

Koichi Izumikawa,

Hiroshi Mukae,

Katsunori Yanagihara

Publication year - 2018

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01971-17

Subject(s) - moxifloxacin , levofloxacin , streptococcus pneumoniae , microbiology and biotechnology , quinolone , mutant , antibacterial agent , in vitro , dna gyrase , drug resistance , ofloxacin , biology , virology , antibiotics , ciprofloxacin , escherichia coli , gene , genetics

Lascufloxacin showed potent activity againstStreptococcus pneumoniae with a GyrA or ParC mutation (first-step mutant). The frequency of selecting resistant strains tended to be lower for lascufloxacin than for levofloxacin and garenoxacin after drug exposure in first-step mutants but was similar in the comparison between lascufloxacin and moxifloxacin. The increase in MIC was smaller for lascufloxacin than for levofloxacin, garenoxacin, and moxifloxacin when clinical strains with only ParC mutations were exposed to the corresponding drug.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research